Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Marcus, Damiënne [VerfasserIn]   i
 Lieverse, Relinde I. Y. [VerfasserIn]   i
 Klein, Carmen [VerfasserIn]   i
 Abdollahi, Amir [VerfasserIn]   i
 Lambin, Philippe [VerfasserIn]   i
 Dubois, Ludwig J. [VerfasserIn]   i
 Yaromina, Ala [VerfasserIn]   i
Titel:Charged particle and conventional radiotherapy
Titelzusatz:current implications as partner for immunotherapy
Verf.angabe:Damiënne Marcus, Relinde I.Y. Lieverse, Carmen Klein, Amir Abdollahi, Philippe Lambin, Ludwig J. Dubois and Ala Yaromina
E-Jahr:2021
Jahr:23 March 2021
Umfang:29 S.
Teil:volume:13
 year:2021
 number:6
 supplement:Special issue
 elocationid:1468
 pages:1-29
 extent:29
Fussnoten:Gesehen am 19.06.2021
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2021
Band/Heft Quelle:13(2021), 6, Special issue, Artikel-ID 1468, Seite 1-29
ISSN Quelle:2072-6694
Abstract:Radiotherapy (RT) has been shown to interfere with inflammatory signals and to enhance tumor immunogenicity via, e.g., immunogenic cell death, thereby potentially augmenting the therapeutic efficacy of immunotherapy. Conventional RT consists predominantly of high energy photon beams. Hypofractionated RT regimens administered, e.g., by stereotactic body radiation therapy (SBRT), are increasingly investigated in combination with cancer immunotherapy within clinical trials. Despite intensive preclinical studies, the optimal dose per fraction and dose schemes for elaboration of RT induced immunogenic potential remain inconclusive. Compared to the scenario of combined immune checkpoint inhibition (ICI) and RT, multimodal therapies utilizing other immunotherapy principles such as adoptive transfer of immune cells, vaccination strategies, targeted immune-cytokines and agonists are underrepresented in both preclinical and clinical settings. Despite the clinical success of ICI and RT combination, e.g., prolonging overall survival in locally advanced lung cancer, curative outcomes are still not achieved for most cancer entities studied. Charged particle RT (PRT) has gained interest as it may enhance tumor immunogenicity compared to conventional RT due to its unique biological and physical properties. However, whether PRT in combination with immune therapy will elicit superior antitumor effects both locally and systemically needs to be further investigated. In this review, the immunological effects of RT in the tumor microenvironment are summarized to understand their implications for immunotherapy combinations. Attention will be given to the various immunotherapeutic interventions that have been co-administered with RT so far. Furthermore, the theoretical basis and first evidences supporting a favorable immunogenicity profile of PRT will be examined.
DOI:doi:10.3390/cancers13061468
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.3390/cancers13061468
 Volltext: https://www.mdpi.com/2072-6694/13/6/1468
 DOI: https://doi.org/10.3390/cancers13061468
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:carbon ion
 charged particle radiation
 clinical trials
 immunogenicity
 immunotherapy
 proton
 radiotherapy
K10plus-PPN:1760886580
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68750705   QR-Code
zum Seitenanfang